https://healthpromotionresearch.org/Faculty Parent Page: Faculty id: 27768 Active Page: Detailsid:27766
Karen Cropsey, PsyD

Karen Cropsey, PsyD

Department of Psychiatry and Behavioral Sciences

karen-cropsey@ou.edu

Dr. Cropsey is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Oklahoma Health Campus and Associate Dean for Clinical Research in the College of Medicine. A licensed clinical psychologist, Cropsey has more than 25 years of experience conducting clinical research focused on substance use disorders, including nicotine, alcohol, and opioid use.

Her research focuses on developing and evaluating accessible, evidence-based interventions to prevent and treat substance use and related health risks. Current research includes remotely delivered interventions for alcohol and tobacco use, opioid overdose prevention, fentanyl test strip education, and sleep and circadian factors among people receiving opioid maintenance treatment. Cropsey's work incorporates innovative approaches such as telehealth, social media recruitment, and digital health technologies to reach underserved populations.

Over the course of their career, Dr. Cropsey has served as principal or multiple principal investigator on more than $20 million in NIH-funded research. Her work has included studies addressing tobacco treatment among people with HIV and individuals involved in the criminal legal system, opioid use disorder, alcohol use, and behavioral health interventions. In 2019, Dr. Cropsey provided expert testimony to the U.S. Senate Committee on Appropriations on the opioid overdose epidemic.

Before joining the University of Oklahoma, Dr. Cropsey served as Vice Chair for Clinical Research in the Department of Psychiatry and Behavioral Neurobiology at the University of Alabama at Birmingham and directed the UAB Center for Addiction and Pain Prevention and Intervention (CAPPI).

Education:

Degree-Granting Institutions
M.S. Virginia Commonwealth University, Richmond, Virginia
Specialization: Biostatistics

Psy.D. Indiana State University, Terre Haute, Indiana
Specialization: Clinical Psychology

Internship Virginia Commonwealth University, Richmond, Virginia
Specialization: Clinical Psychology (APA-accredited)

M.S. University of Wisconsin-Madison, Madison, Wisconsin
Specialization: Education Psychology

B.S. University of Wisconsin-Madison, Madison, Wisconsin
Major: Psychology

Postgraduate Training
Post-doc Virginia Commonwealth University, Richmond, Virginia, October 2002
Specialization: Addiction

Post-doc University of Mississippi Medical Center, Jackson,
Mississippi, April 2000
Specialization: Forensic Psychology

Funding:

UG1DA013727; MPI: Barth (contact), Brady
11/01/2019-05/30/2032
NIH/NIDA (subaward from MUSC)
$69,506
Southern Consortium Node of the Clinical Trials Network
UAB will work in collaboration with MUSC as a site for NIDA Clinical Trials Network projects
Role: Site PI

1UG3TR004797-01A1; MPI: Hawk (contact), Mahoney
NCATS/NIH $2,136,696
Improving Efficiency, Quality, and Equity: Randomized Controlled Evaluations of Remote vs. In-Person Clinical Trial Methods
This project will compare in person to remote methods in clinical trials research among three different behavioral/pharmacotherapy clinical trials: 1)smoking cessation with NRT; 2)use of a depression app; 3)naloxone training and kit to prevent overdose.
This project will determine if in person methods can provide
similar or superior recruitment, retention and intervention delivery rigor as traditional in person clinical trials.
Role: Site PI

R01DA059471; MPI: Cropsey (contact),Gamble 
09/30/23-08/31/27
NIH/NIDA $4,402,639
Medications for opioid use disorder differentially modulate intrinsically photosensitive retinal ganglion cell function, sleep, and circadian rhythms: implications for treatment
In this project we will explore how opioids cause sleep disturbance and circadian misalignment among intrinsically photosensitive retinal ganglion cells (ipRGCs) in the retina of the eye among persons maintained on medications for opioid use disorder.

R01CA284649; PI: Smith (contact), Carpenter
07/01/23-06/30/28
NIH/NCI (subaward from MUSC) $855,149
A clinical trial of adaptive treatment for early smoking cessation relapse
In this multi-site trial (South Caroline and Alabama), we will test whether staying the course or switching to a different pharmacotherapy (or to a reduced harm product) during early treatment nonresponse is helpful for eventual smoking cessation.
Role: Site PI

P01AA029540; MPI: Cropsey (contact), Vinikoor
09/10/2021-08/31/2026
NIH/NIAAA $5,703,886
Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA)
Unhealthy alcohol use represents an unaddressed barrier to achieving and maintaining control of the HIV epidemic globally. In the Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA), we will compare the effectiveness of an alcohol brief intervention and a transdiagnostic cognitive behavioral therapy-based model that can address unhealthy alcohol use and a range of comorbid mental health problems to improve HIV and alcohol outcomes among low-resource and underserved patients with HIV and unhealthy alcohol use in
sub-Saharan Africa and the Southern United States.

R01DA046096-01A1; MPI: Cropsey (contact), Gamble
07/15/20-04/30/26 (NCE)
NIH/NIDA $2,779,141
Circadian and sleep mechanisms among racial groups for nicotine dependence, craving, and withdrawal
The goal of this project is to examine how sleep and circadian misalignment maintain nicotine use.

Select Publications:

For a complete list of published works available at: https://pubmed.ncbi.nlm.nih.gov/?term=Cropsey+K&sort=date)